Version 7.1: Summary of changes

For the ART section

• Addition of DTG with ABC+3TC or TDF+FTC to the first line combination treatment recommendations
• Change of alternative treatment combination recommendations to include DRV/r + RAL (if CD4 count> 200 cells/mmc and VL < 100.000 copies/mL) and LPV/r + 3TC, and exclusion of older drugs as ddI, SQV and FPV as recommended alternative components
• Considerations of treating all cases of acute HIV infection, preferably in the context of a clinical trial
• Addition of LPV/r+3TC and ATV/r+3TC as possible switch strategy options for virologically suppressed persons with a comment that these are probably better options than monotherapy with LPV/r or DRV/r

For the Co-morbidity section

• All adverse events and drug-drug interaction tables were updated and include information on DTG and EVG + COBI
• The CVD and hypertension diagnosis and treatment indication algorithms were updated with new treatment limits

For the Co-infection section

The recommendations on HCV care were updated to include

• Interferon-free DAA combinations to be considered standard of care for chronic HCV
• 2 new tables summarizing current interferon-containing and –free treatment options have been included, and will be updated again shortly to reflect the licensing of 2 additional DAA combinations
• A table summarizing the current PK data on DAA and ARV was included and careful checking for drug interactions is urgently recommended prior to starting HCV therapy due to drug-drug interactions (in particular HIV and HCV PIs)

For the opportunistic infection section

• Revision of primary- and secondary prophylaxis and treatment for all OIs
• Expansion of the TB section
• Addition of Leishmaniasis care information